<h4>Background</h4>Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer is the most prevalent subtype among women but has a modest response to neoadjuvant chemotherapy (NAC). Here, ERBB2 is linked to breast carcinoma.